FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380244606> ?p ?o ?g. }

• W4380244606 abstract "Interleukin-34 (IL-34) is expressed by keratinocytes in the skin and plays a role in Langerhans cell (LC) homeostasis through its binding to the colony-stimulating factor 1 receptor (CSF-1R) ( Greter et al., 2012 Greter M. Lelios I. Pelczar P. Hoeffel G. Price J. Leboeuf M. et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity. 2012; 37: 1050-1060 Abstract Full Text Full Text PDF PubMed Scopus (280) Google Scholar ; Wang et al., 2012 Wang Y. Szretter K.J. Vermi W. Gilfillan S. Rossini C. Cella M. et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012; 13: 753-760 Crossref PubMed Scopus (652) Google Scholar ). In recent years, a growing body of literature has reported its overexpression during inflammation in tissues and/or in the serum of patients with rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases or Sjogren’s syndrome, in association with disease severity ( Munoz-Garcia et al., 2021 Munoz-Garcia J. Cochonneau D. Teletchea S. Moranton E. Lanoe D. Brion R. et al. The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis. Theranostics. 2021; 11: 1568-1593 Crossref PubMed Scopus (31) Google Scholar ). By contrast, some immunoregulatory properties of IL-34 have also been described in other physiopathological contexts, either by controlling the expression of proinflammatory cytokines or by promoting M2 macrophage differentiation and Treg cell functions ( Guillonneau et al., 2017 Guillonneau C. Bézie S. Anegon I. Immunoregulatory properties of the cytokine IL-34. Cell Mol Life Sci. 2017; 74: 2569-2586 Crossref PubMed Scopus (67) Google Scholar ). Although IL-34 is mainly produced in the skin, very few studies have investigated its expression, regulation and role during skin inflammation and it is still unclear whether IL-34 has a beneficial or a deleterious role. Li et al. reported low serum concentrations of IL-34 in psoriasis patients similar to those of healthy controls ( Li et al., 2017 Li J. Liu L. Rui W. Li X. Xuan D. Zheng S. et al. New Interleukins in Psoriasis and Psoriatic Arthritis Patients: The Possible Roles of Interleukin-33 to Interleukin-38 in Disease Activities and Bone Erosions. Dermatology. 2017; 233: 37-46 Crossref PubMed Scopus (67) Google Scholar ), without investigating IL-34 tissue expression. By contrast, Esaki et al. reported a reduced IL-34 expression in skin lesions of atopic dermatitis (AD) patients, suggesting that IL-34 could have immunoregulatory properties in the skin ( Esaki et al., 2015 Esaki H. Ewald D.A. Ungar B. Rozenblit M. Zheng X. Xu H. et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol. 2015; 135: 153-163 Abstract Full Text Full Text PDF PubMed Google Scholar )." @default.
• W4380244606 created "2023-06-12" @default.
• W4380244606 creator A5003398023 @default.
• W4380244606 creator A5004590163 @default.
• W4380244606 creator A5006023928 @default.
• W4380244606 creator A5013922423 @default.
• W4380244606 creator A5014993959 @default.
• W4380244606 creator A5015131799 @default.
• W4380244606 creator A5017481327 @default.
• W4380244606 creator A5022863537 @default.
• W4380244606 creator A5032180454 @default.
• W4380244606 creator A5033161345 @default.
• W4380244606 creator A5035808343 @default.
• W4380244606 creator A5039656288 @default.
• W4380244606 creator A5041853102 @default.
• W4380244606 creator A5042663790 @default.
• W4380244606 creator A5047735315 @default.
• W4380244606 creator A5057222564 @default.
• W4380244606 creator A5060169795 @default.
• W4380244606 creator A5083493003 @default.
• W4380244606 date "2023-06-01" @default.
• W4380244606 modified "2023-10-12" @default.
• W4380244606 title "Interleukin 34 exerts anti-inflammatory activities on keratinocytes and is down-regulated in psoriatic-inflamed skin" @default.
• W4380244606 cites W1616393669 @default.
• W4380244606 cites W1893975780 @default.
• W4380244606 cites W1994581225 @default.
• W4380244606 cites W2015589285 @default.
• W4380244606 cites W2033985800 @default.
• W4380244606 cites W2050568107 @default.
• W4380244606 cites W2343795213 @default.
• W4380244606 cites W2593594734 @default.
• W4380244606 cites W2711821646 @default.
• W4380244606 cites W3112360201 @default.
• W4380244606 doi "https://doi.org/10.1016/j.jid.2023.05.023" @default.
• W4380244606 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37315881" @default.
• W4380244606 hasPublicationYear "2023" @default.
• W4380244606 type Work @default.
• W4380244606 citedByCount "0" @default.
• W4380244606 crossrefType "journal-article" @default.
• W4380244606 hasAuthorship W4380244606A5003398023 @default.
• W4380244606 hasAuthorship W4380244606A5004590163 @default.
• W4380244606 hasAuthorship W4380244606A5006023928 @default.
• W4380244606 hasAuthorship W4380244606A5013922423 @default.
• W4380244606 hasAuthorship W4380244606A5014993959 @default.
• W4380244606 hasAuthorship W4380244606A5015131799 @default.
• W4380244606 hasAuthorship W4380244606A5017481327 @default.
• W4380244606 hasAuthorship W4380244606A5022863537 @default.
• W4380244606 hasAuthorship W4380244606A5032180454 @default.
• W4380244606 hasAuthorship W4380244606A5033161345 @default.
• W4380244606 hasAuthorship W4380244606A5035808343 @default.
• W4380244606 hasAuthorship W4380244606A5039656288 @default.
• W4380244606 hasAuthorship W4380244606A5041853102 @default.
• W4380244606 hasAuthorship W4380244606A5042663790 @default.
• W4380244606 hasAuthorship W4380244606A5047735315 @default.
• W4380244606 hasAuthorship W4380244606A5057222564 @default.
• W4380244606 hasAuthorship W4380244606A5060169795 @default.
• W4380244606 hasAuthorship W4380244606A5083493003 @default.
• W4380244606 hasBestOaLocation W43802446062 @default.
• W4380244606 hasConcept C164027704 @default.
• W4380244606 hasConcept C203014093 @default.
• W4380244606 hasConcept C2776914184 @default.
• W4380244606 hasConcept C2778379841 @default.
• W4380244606 hasConcept C2778690821 @default.
• W4380244606 hasConcept C71924100 @default.
• W4380244606 hasConcept C74172505 @default.
• W4380244606 hasConcept C8891405 @default.
• W4380244606 hasConceptScore W4380244606C164027704 @default.
• W4380244606 hasConceptScore W4380244606C203014093 @default.
• W4380244606 hasConceptScore W4380244606C2776914184 @default.
• W4380244606 hasConceptScore W4380244606C2778379841 @default.
• W4380244606 hasConceptScore W4380244606C2778690821 @default.
• W4380244606 hasConceptScore W4380244606C71924100 @default.
• W4380244606 hasConceptScore W4380244606C74172505 @default.
• W4380244606 hasConceptScore W4380244606C8891405 @default.
• W4380244606 hasLocation W43802446061 @default.
• W4380244606 hasLocation W43802446062 @default.
• W4380244606 hasLocation W43802446063 @default.
• W4380244606 hasOpenAccess W4380244606 @default.
• W4380244606 hasPrimaryLocation W43802446061 @default.
• W4380244606 hasRelatedWork W1863985305 @default.
• W4380244606 hasRelatedWork W1992848314 @default.
• W4380244606 hasRelatedWork W2015667478 @default.
• W4380244606 hasRelatedWork W2392126385 @default.
• W4380244606 hasRelatedWork W2416795054 @default.
• W4380244606 hasRelatedWork W2571013527 @default.
• W4380244606 hasRelatedWork W2944714515 @default.
• W4380244606 hasRelatedWork W3029774148 @default.
• W4380244606 hasRelatedWork W3039146159 @default.
• W4380244606 hasRelatedWork W4379052364 @default.
• W4380244606 isParatext "false" @default.
• W4380244606 isRetracted "false" @default.
• W4380244606 workType "article" @default.